A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding. Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More
News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW. This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research. The top stories: … Read More
A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma. Talvey (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide showed a progression-free survival rate of up to 81.3% versus standard of care (51.2%) and an overall survival… Read More
A single pill low-dose combination therapy could reduce the risk of recurrent stroke by almost 40%, trial results show. GMRx2, developed by biopharmaceutical company George Medicines, reduced recurrent stroke risk in patients with previous intracerebral haemorrhage (ICH) by 39% compared to placebo, according to results published in the New… Read More
Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust. Patients with advanced squamous cell anal carcinoma (SCAC) are usually treated with chemotherapy. Results… Read More
Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug. For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer… Read More
Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical. Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no,… Read More
Scientists have found a way to combine a precision drug therapy with an antibody and radiation to eliminate tumours without causing side effects. “This is a one-two punch,” said Charly Craik, Professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF) and co-senior author of the… Read More
Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 2, Wednesday 15 November 2023, the tracks include: Engineering antibodies, emerging targets and therapeutic approaches, advancing bispecifics and combination… Read More
Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific… Read More
